Victory Capital Management
OVID icon

Victory Capital Management’s Ovid Therapeutics OVID Stock Holding History

Victory Capital Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52K Buy
19,348
+6,182
+47% +$16K ﹤0.01% 2393
2026
Q1 		$29.2K Buy
+13,166
New +$23.5K ﹤0.01% 2357
2020
Q2 		– Sell
-5,937
Closed -$18K – 3041
2020
Q1 		$18K Buy
+5,937
New +$20K ﹤0.01% 2877
2019
Q4 		– Sell
-4,694
Closed -$15K – 3072
2019
Q3 		$15K Buy
+4,694
New +$10.7K ﹤0.01% 3136
2018
Q1 		– Sell
-105,470
Closed -$1.04M – 1895
2017
Q4 		$1.04M Buy
105,470
+4,440
+4% +$40.8K ﹤0.01% 1219
2017
Q3 		$866K Sell
101,030
-29,970
-23% -$250K ﹤0.01% 1241
2017
Q2 		$1.37M Buy
+131,000
New +$1.71M ﹤0.01% 1088

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Victory Capital Management's OVID Position: Q2 2026 in Review

Victory Capital Management increased its Ovid Therapeutics (OVID) stake by 47% in Q2 2026, buying an estimated $16K and bringing the position to 19,348 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #2393.

Victory Capital Management first reported a position in OVID in Q2 2017 and has held it in 7 quarters since. The position peaked at $1.37M in Q2 2017. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Victory Capital Management held 19,348 shares of Ovid Therapeutics worth $52K as of Q2 2026.
  • Victory Capital Management bought 6,182 Ovid Therapeutics shares in Q2 2026, an estimated $16K.
  • Ovid Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2393 holding.
  • Victory Capital Management first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 7 quarters since.
  • Victory Capital Management's Ovid Therapeutics position peaked at $1.37M in Q2 2017.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.